LENZ Therapeutics (NASDAQ:LENZ) Stock: Insider Ra Capital Management, L.P. Sells 2,718,684 Shares

LENZ Therapeutics, Inc. (NASDAQ:LENZ) major shareholder Ra Capital Management, L.P. sold 2,718,684 shares of the firm’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $3.36, for a total value of $9,134,778.24. Following the transaction, the insider owned 57,559 shares in the company, valued at approximately $193,398.24. This trade represents a 97.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

LENZ Therapeutics Stock Up 14.8%

LENZ stock opened at $3.50 on Wednesday. The business has a 50-day simple moving average of $4.01 and a 200 day simple moving average of $7.96. The company has a market cap of $109.97 million, a PE ratio of -0.78 and a beta of 0.78. LENZ Therapeutics, Inc. has a 52 week low of $2.80 and a 52 week high of $32.13.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). LENZ Therapeutics had a negative return on equity of 56.10% and a negative net margin of 1,134.97%. The firm had revenue of $3.38 million for the quarter, compared to the consensus estimate of $4.20 million. On average, analysts anticipate that LENZ Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on LENZ shares. Weiss Ratings lowered LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. Zacks Research raised shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Citigroup reaffirmed a “buy” rating on shares of LENZ Therapeutics in a research report on Wednesday, August 12th. Piper Sandler decreased their target price on LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating for the company in a research report on Monday, October 19th. Finally, HC Wainwright lowered their price objective on shares of LENZ Therapeutics to $16.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $17.50.

Institutional Trading of LENZ Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Blue Owl Capital Holdings LP bought a new position in LENZ Therapeutics in the 2nd quarter worth approximately $4,298,000. Bank of America Corp DE raised its holdings in LENZ Therapeutics by 377.4% during the 1st quarter. Bank of America Corp DE now owns 547,534 shares of the company’s stock valued at $5,010,000 after acquiring an additional 432,846 shares during the period. Jefferies Financial Group Inc. bought a new stake in LENZ Therapeutics during the 2nd quarter valued at $1,138,000. BlackRock Inc. bought a new stake in LENZ Therapeutics during the 2nd quarter valued at $13,019,000. Finally, Squarepoint Ops LLC lifted its position in shares of LENZ Therapeutics by 16.0% during the second quarter. Squarepoint Ops LLC now owns 1,747,096 shares of the company’s stock worth $9,924,000 after acquiring an additional 240,597 shares in the last quarter. Institutional investors own 54.32% of the company’s stock.

Key LENZ Therapeutics News

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, including narrowing its projected FY2027 loss to $1.30 per share from $4.14 and increasing its FY2030 profit estimate to $1.09 from $0.63. The firm maintains a Buy rating, though its outlook still projects losses through FY2029.
• Negative Sentiment: Major shareholder RA Capital Management sold 2.72 million shares for about $9.1 million, reducing its position by 97.93% and leaving it with 57,559 shares. Such a large sale may create pressure on the stock or concern investors about insider confidence. Article: LENZ Therapeutics major shareholder sells stock
• Negative Sentiment: Analyst price expectations were also reduced: HC Wainwright cut its target to $16, while the reported consensus target fell 25% to $15.30. Article: LENZ stock gets price target reduction from HC Wainwright Article: LENZ consensus price target decreased
• Negative Sentiment: LENZ’s latest quarter also fell short of expectations: its $0.99-per-share loss exceeded the $0.89 consensus loss, and revenue of $3.38 million missed estimates of $4.20 million.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.